San Francisco, California, United States The main department of described VC is located in the San Francisco. The company was established in North America in United States.
Besides them, we counted 1 critical employee of this fund in our database.
Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund. For fund there is a match between the location of its establishment and the land of its numerous investments - United States. The fund has specific favorite in a number of founders of portfolio startups. When startup sums 4 or 5+ of the founder, the probability for it to get the investment is little. Among the most popular fund investment industries, there are Biotechnology, Health Diagnostics. Among the most popular portfolio startups of the fund, we may highlight CardioDx, moksha8 Pharmaceuticals, DNAnexus.
The usual things for fund are deals in the range of 10 - 50 millions dollars. The increased amount of exits for fund were in 2014. The top activity for fund was in 2017. Despite it in 2019 the fund had an activity. The real fund results show that this VC is 11 percentage points more often commits exit comparing to other companies. This TPG Biotech works on 5 percentage points less the average amount of lead investments comparing to the other organizations. The fund is generally included in 2-6 deals every year.
The standard case for the fund is to invest in rounds with 4-5 partakers. Despite the TPG Biotech, startups are often financed by Kleiner Perkins, TPG Growth, Novo Ventures. The meaningful sponsors for the fund in investment in the same round are Novo Ventures, Kleiner Perkins, OrbiMed. In the next rounds fund is usually obtained by Novo Ventures, Mohr Davidow Ventures, Longitude Capital.
Related Funds
Funds with similar focus
| Fund Name | Location |
| Asatsu DK | Hokkaido Prefecture, Japan, Sapporo |
| Beijing Yansai Luyou Touzi Co., Ltd. | Beijing, China, Huairou |
| Beta Bridge Capital | New Jersey, Princeton, United States |
| C-Bridge Capital | New York, New York, United States |
| CNBC | Englewood Cliffs, New Jersey, United States |
| Cohen & Steers Inc. | New York, New York, United States |
| Crossroads Capital | Colorado, Greenwood Village, United States |
| DCapital | - |
| JFE Engineering | Chiyoda, Japan |
| Kensington Partners | Australia, Perth, Western Australia |
| Omron Ventures | Chiba, Japan, Minato |
| Shenzhen Huapengfei Modern Logistics | China, Guangdong, Shenzhen |
| Stonehenge Partners Inc. | Columbus, Ohio, United States |
| SuRo Capital | California, San Francisco, United States |
| TOM Capital Associates | Alberta, Calgary, Canada |
| Voqal | Colorado, Longmont, United States |
| Xingfan Touzi | China, Ningbo, Zhejiang |
| Xinyu Xinchengzhang | China, Guangdong, Jiangxi |
| Yajie Shanghui | Beijing, China, Haidian |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Carisma Therapeutics | $30M | 21 Sep 2022 | Philadelphia, Pennsylvania, United States | ||
Carisma Therapeutics | $12M | 01 Mar 2021 | Philadelphia, Pennsylvania, United States | ||
Carisma Therapeutics | $47M | 07 Jan 2021 | Philadelphia, Pennsylvania, United States | ||
Azura Ophthalmics | $20M | 22 Oct 2020 | Tel Aviv District | ||
Avalyn Pharma | $35M | 27 Apr 2020 | Seattle, Washington, United States | ||
Satsuma Pharmaceuticals | $62M | 24 Apr 2019 | South San Francisco, California, United States | ||
Fusion Pharmaceuticals | $105M | 01 Apr 2019 | Hamilton, Ontario, Canada | ||
Trevi Therapeutics | $10M | 01 Jan 2019 | Connecticut, United States | ||
Trevi Therapeutics | $10M | 01 Aug 2018 | Connecticut, United States |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Carisma Therapeutics | $30M | 21 Sep 2022 | Philadelphia, Pennsylvania, United States | ||
Carisma Therapeutics | $12M | 01 Mar 2021 | Philadelphia, Pennsylvania, United States | ||
Carisma Therapeutics | $47M | 07 Jan 2021 | Philadelphia, Pennsylvania, United States | ||
Azura Ophthalmics | $20M | 22 Oct 2020 | Tel Aviv District | ||
Avalyn Pharma | $35M | 27 Apr 2020 | Seattle, Washington, United States | ||
Satsuma Pharmaceuticals | $62M | 24 Apr 2019 | South San Francisco, California, United States | ||
Fusion Pharmaceuticals | $105M | 01 Apr 2019 | Hamilton, Ontario, Canada | ||
Trevi Therapeutics | $10M | 01 Jan 2019 | Connecticut, United States | ||
Trevi Therapeutics | $10M | 01 Aug 2018 | Connecticut, United States |
